GSK Pharma Slapped Rs 38.06 Cr Decree by Bombay Court in Legacy Property Dispute
Mumbai: Drugmaker GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) has received a decree from the Court of Small Causes, Bombay, involving a total demand of Rs 38.06 crore related to mesne profits for office premises earlier used by erstwhile Burroughs Wellcome (India) Limited, with the company stating that it is evaluating the order and may file an appeal to mitigate the financial impact.
According to the disclosure made with the exchange, the decree was dated 6 May 2025 and was received by the company on 2 November 2025. The order pertains to mesne profits amounting to ₹87.09 lakh, along with simple interest at the rate of 9% per annum from June 2001, aggregating to ₹37.19 crore, taking the total demand to ₹38.06 crore.
The company clarified that the matter relates to office premises occupied more than 24 years ago by Burroughs Wellcome (India) Limited, prior to its merger with GlaxoSmithKline Pharmaceuticals Limited. GSK Pharma stated that it did not have prior records or logs of the case, which resulted in delayed confirmation of attribution and subsequent intimation to the exchanges.
In terms of impact, the company said it is currently assessing the decree and its implications on financial and operational activities. GSK Pharma added that it will take appropriate legal steps, including filing an appeal in due course, to safeguard its interests and mitigate any potential impact arising from the order.
The disclosure was formally addressed to BSE Limited and the National Stock Exchange of India Limited, and was signed by Ajay Nadkarni, Vice President – Administration, Real Estate & Company Secretary, on behalf of the company.
According to the regulatory filing submitted by GlaxoSmithKline Pharmaceuticals Limited, the decree arises from a long-pending legacy matter and does not involve any recent operational activity of the company.
